LYMPHOMA, LARGE B-CELL, DIFFUSE
Clinical trials for LYMPHOMA, LARGE B-CELL, DIFFUSE explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, LARGE B-CELL, DIFFUSE trials appear
Sign up with your email to follow new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug trial aims to beat standard treatment for aggressive lymphoma
Disease control Recruiting nowThis study is testing whether a new drug combination works better than the current standard treatment for a fast-growing blood cancer called GCB DLBCL. Researchers will compare zilovertamab vedotin plus R-CHP against polatuzumab vedotin plus R-CHP in 594 people who haven't had an…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Two-Pronged attack: experimental therapy targets tough lymphomas
Disease control Recruiting nowThis study is testing a new type of personalized immune cell therapy called prizlo-cel for adults with B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments, or for those with newly diagnosed high-risk disease. The therapy involves collecting a pat…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Last-Chance cell therapy offered when standard drug fails quality checks
Disease control AVAILABLEThis program provides access to a non-standard version of a personalized cell therapy (lisocabtagene maraleucel) for adults with a type of aggressive lymphoma. It is for patients who were already prescribed this therapy, but the specific batch made for them did not pass all stand…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
New hope for Tough-to-Treat lymphoma: experimental combo enters Mid-Stage trial
Disease control Recruiting nowThis study is testing whether adding two newer drugs, glofitamab and polatuzumab, to a standard chemotherapy regimen (R-CHP) works better for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. About 40 participants will receive the drug combination for up to 8 …
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC